Evidence map›Paper›PMID 41577869›Full record

ReviewNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026

Investigating the efficacy, methods, and challenges of induced pluripotent stem cells (iPSC) therapy in Parkinson's disease.

Mohammed Ahmed Mustafa, Shaker Al-Hasnaawei, Irwanjot Kaur, Malathi H, Laxmidhar Maharana, Archana Dhyani, Ashish Singh Chauhan, Jatin Sharma, Deepak Nathiya

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohammed Ahmed MustafaDepartment of Biology, College of Education, University of Samarra, Samarra, 34010, Iraq.
Shaker Al-HasnaaweiCollege of Pharmacy, the Islamic University, Najaf, Iraq.
Irwanjot KaurDepartment of Allied Healthcare and Sciences, Vivekananda Global University, Jaipur, Rajasthan, 303012, India.
Malathi HDepartment of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to Be University), Bangalore, Karnataka, India.
Laxmidhar MaharanaDepartment of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to Be University), Bhubaneswar, Odisha-751030, India.ORCID http://orcid.org/0000-0002-0424-0875
Archana DhyaniDepartment of Pharmacy, Graphic Era Hill University, Dehradun, India.
Ashish Singh ChauhanDivision of Research and Innovation, Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, Uttarakhand, India.
Jatin SharmaCentre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India.
Deepak NathiyaDepartment of Pharmacy Practice, NIMS Institute of Pharmacy, NIMS University Rajasthan, Jaipur, India. dnathiya@nimsuniversity.org.ORCID http://orcid.org/0009-0009-6681-4529

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative disorders like Parkinson's disease (PD) are defined by the gradual degeneration of neurons across various regions of the central nervous system, which ultimately leads to brain dysfunction in the affected patients. The utilization of stem cell-based approaches, encompassing fetal ventral mesencephalic cells, human embryonic stem cells (hESCs), and human induced pluripotent stem cells (hiPSCs), holds great promise for PD patients. The modeling of neurodegenerative diseases using stem cells provides a valuable platform to screen potential therapeutic agents and investigate disease mechanisms. However, the common clinical use of stem cell therapies is hindered by related ethical concerns, the risk of immunological rejection, and the lack of established grafting protocols. The conversion of differentiated adult cells into induced pluripotent stem cells (iPSCs) has sparked renewed optimism for the progress of cell-based replacement therapeutic approaches. This review highlights the recent progress in the application of stem cell technologies, specifically the utilization of hiPSCs, for the treatment of PD. Additionally, the review discusses the potential of hiPSCs in PD, which can facilitate the translation of iPSC-based approaches into clinical settings for PD treatment.

Indexed as

Induced Pluripotent Stem CellsParkinson DiseaseStem Cell TransplantationAnimalsHumansCell therapyDopaminergic neuronsInduced pluripotent stem cellParkinson’s disease

Identifiers

PMID41577869

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.